Crown Equity Holdings Inc. is publicly traded with the symbol CRWE. The Company primarily provides and offers advertising, branding, marketing solutions and services to boost customer awareness, as well as merchant visibility as a worldwide online multi-media publisher. For list of services offered click here

SAN DIEGO, CA - (NewMediaWire) - October 08, 2015 - Youngevity International, Inc. (OTCQX: YGYI) (www.YGYI.com), a global direct marketer of nutritional and lifestyle products and also a vertically-integrated producer of gourmet coffees for the commercial, retail and direct sales channels, announced the Ministry of Health of the Russian Federation has approved its core product line for distribution across Russia.

LLC Youngevity Russia, a wholly owned subsidiary of Youngevity, was formed on July 4, 2014 and the Company officially opened an office in Moscow in November of last year. LLC Youngevity Russia has been working since its inception, in cooperation with the Ministry of Health, to gain the necessary product approvals to properly enter the Russian market. Initially, product approvals happened relatively quickly, but the significant amount of ingredients present in Youngevity's core 90 for Life Product Line took longer than anticipated to gain approval. This week the Company announced the approval of its 90 for Life product line which includes Beyond Tangy Tangerine 2.0, Osteo Fx, and Ultimate EFA.

Steve Wallach, Youngevity's CEO, stated, "Our team has been working tirelessly on these product approvals and we are proud to finally be in a position to launch an effective sales and marketing campaign in Russia."

Ricardo Spilman, Director of Sales and Operations for Eastern Europe and Israel, stated, "This is a very exciting time for Youngevity Russia. We now have our core product approvals which is what we needed to penetrate the market. Youngevity's product line will invigorate our distributors and help drive consumption of the other Youngevity products that have been approved for the territory."

The Company advised that in addition to the 90 for Life Products the company has gained approval to market a complete line of health and beauty products, Essential Oils, a complete line of coffees, CM Cream, Pollen Burst, a weight loss program, Root Beer Belly, and Imortalium.

About Youngevity International, Inc.Youngevity International Inc. (OTCQX: YGYI) (www.YGYI.com) is a fast-growing, innovative, multi-dimensional company that offers a wide range of consumer products and services, primarily through person-to-person selling relationships that comprise a "network of networks." The Company also is a vertically-integrated producer of the finest coffees for the commercial, retail and direct sales channels. The Company was formed after the merger of Youngevity Essential Life Sciences (www.Youngevity.com) and Javalution Coffee Company in the summer of 2011, and changed its name to Youngevity International Inc. from AL International, Inc. in July 2013. For more information, visit www.YGYI.com or find us on Facebook or follow us on Twitter @youngevity.

Safe Harbor StatementThis release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "excited", "believes," "estimates," and similar expressions. The forward-looking statements contained in this press release include statements regarding the expected timing of availability of Café La Rica, expected expansion of its distribution, continued traction of Café La Rica, our belief that building company owned brands over the long run will greatly contribute to creating shareholder value. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict, including our ability to increase distribution and our ability to continue our current growth. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.